Skip to Content

Tisotumab vedotin FDA Approval Status

FDA Approved: No
Generic name: tisotumab vedotin
Company: Genmab A/S and Seagen Inc.
Treatment for: Cervical Cancer

Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) in development for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Development Timeline for tisotumab vedotin

DateArticle
Feb 10, 2021Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Jun 29, 2020Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Jun 16, 2017Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.